Journal article icon

Journal article

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)

Abstract:

Aims

Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3-LVH trial will test the hypothesis that the β3 adrenergic receptor agonist mirabegron will improve LV hypertrophy and diastolic function in patients with hypertensive structural heart disease at high risk for developing heart failure with pres...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/ehf2.12306

Authors


Expand authors...
More from this funder
Grant:
UE LSHM-CT-05-018833
National Institute for Health Research More from this funder
Publisher:
Wiley Publisher's website
Journal:
ESC Heart Failure Journal website
Volume:
5
Issue:
5
Pages:
830-841
Publication date:
2018-06-22
Acceptance date:
2018-04-22
DOI:
EISSN:
2055-5822
Pmid:
29932311
Source identifiers:
859580
Language:
English
Keywords:
Pubs id:
pubs:859580
UUID:
uuid:309bb308-06c1-4829-9349-6a49a139c6f1
Local pid:
pubs:859580
Deposit date:
2018-10-18

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP